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Abstract
Background: HIV-1-infected elite controllers or suppressors (ES) maintain undetectable viral loads (< 50 copies/mL)
without antiretroviral therapy. The mechanisms of suppression are incompletely understood. Modulation of HIV-1
replication by miRNAs has been reported, but the role of small RNAs in ES is unknown. Using samples from a well-
characterized ES cohort, untreated viremic patients, and uninfected controls, we explored the PBMC miRNA profile
and probed the relationships of miRNA expression, CD4+ T-cell counts, and viral load.
Results: miRNA profiles, obtained using multiple acquisition, data processing, and analysis methods, distinguished ES
and uninfected controls from viremic HIV-1-infected patients. For several miRNAs, however, ES and viremic patients
shared similar expression patterns. Differentially expressed miRNAs included those with reported roles in HIV-1 latency
(miR-29 family members, miRs -125b and -150). Others, such as miR-31 and miR-31*, had no previously reported
connection with HIV-1 infection but were found here to differ significantly with uncontrolled HIV-1 replication.
Correlations of miRNA expression with CD4+ T-cell count and viral load were found, and we observed that ES with low
CD4+ T-cell counts had miRNA profiles more closely related to viremic patients than controls. However, expression
patterns indicate that miRNA variability cannot be explained solely by CD4+ T-cell variation.
Conclusions: The intimate involvement of miRNAs in disease processes is underscored by connections of miRNA
expression with the HIV disease clinical parameters of CD4 count and plasma viral load. However, miRNA profile
changes are not explained completely by these variables. Significant declines of miRs-125b and -150, among
others, in both ES and viremic patients indicate the persistence of host miRNA responses or ongoing effects of
infection despite viral suppression by ES. We found no negative correlations with viral load in viremic patients, not
even those that have been reported to silence HIV-1 in vitro, suggesting that the effects of these miRNAs are
exerted in a focused, cell-type-specific manner. Finally, the observation that some ES with low CD4 counts were
consistently related to viremic patients suggests that miRNAs may serve as biomarkers for risk of disease
progression even in the presence of viral suppression.
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Background
Untreated HIV-1 infection is characterized by viral repli-
cation and leads to suppression of the immune system
and eventual death in most cases. A minority of indivi-
duals, known as elite controllers or elite suppressors
(ES), are able in the absence of antiretroviral treatment
to resist progression to HIV disease and to maintain
peripheral blood viral loads below the limit of detection
of current clinical assays (50 copies/mL). The mechan-
isms whereby this control is achieved remain incomple-
tely understood despite substantial advances in recent
years in the characterization of both host and viral fac-
tors associated with elite suppression [1-3]. Because a
deeper understanding of this phenomenon may facilitate
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and therapy design, we initiated studies of elite suppres-
sion in a relatively new area: the epigenetic realm of
small RNA [4].
To date, associations of host microRNA (miRNA)
expression with HIV-1 elite suppression have not been
described in the literature;h o w e v e r ,t h e r eh a sb e e na
strong focus on miRNA in cancer research and, increas-
ingly, in investigations of infectious disease. miRNAs
associated with medical conditions may serve as valuable
biomarkers [5], especially when present and detectable in
easily accessed body fluids, and clinical assays are cur-
rently under development for diagnosing and staging spe-
cific cancers or monitoring response to treatment. We
recently reported that plasma miRNAs upregulated dur-
ing acute phase infection predict progression in a model
of HIV-associated central nervous system disease [6].
T h er o l eo fm i R N Ai nd i s e a s ei s not restricted to that of
bystander or simple consequence of disease processes.
miRNAs are often directly involved in etiology and/or
response, opening the door to miRNA-based therapies
[7,8]. In Hepatitis C virus infection, the liver-enriched
miR-122 is required by the virus for optimal replication
[9,10]. Inhibiting the action of miR-122 appears to be a
viable therapeutic option [11], with an inhibitor currently
in phase II trials.
Although the role of miRNA in elite control of HIV-1 is
unexplored, multiple studies have examined miRNAs in
HIV infection [12]. Several groups have examined the pos-
sibility that HIV, like some other viruses, encodes its own
miRNAs, which could be processed by cellular machinery
[13,14]. Others have probed the effects of HIV on miRNA
expression in cell lines or primary cells infected or trans-
fected with HIV [15-19]. Five miRNAs–miRs -28, -125b,
-150, -223, and -382–have been implicated in regulation
of HIV-1 transcripts through the viral UTR in CD4+ T
cells [15]. Other studies have explored the potential role of
these miRNAs in the differing susceptibility to infection of
monocytes and macrophages [20,21]. Regulatory networks
of HIV, miRNAs, antiviral proteins, and miRNA proces-
sing enzymes have also been probed [16,22-24]. Impor-
tantly, recent work has investigated the in vivo expression
and roles of miRNAs during lentiviral infection: in periph-
eral blood mononuclear cells (PBMC) [25], brain tissue
[26-28], and plasma [6]. Additional studies and replication
will aid the research community in drawing overarching
and actionable conclusions.
To investigate the contribution of miRNA-mediated
regulation to elite suppression of HIV-1 and to expand
our knowledge of HIV and miRNAs in general, we pro-
filed miRNA expression and examined clinical correlates
using control, uninfected donors, a well-characterized
cohort of elite suppressors, and untreated, viremic HIV-1
infected individuals. We chose to examine PBMC
miRNA expression rather than focusing on subsets of
cells for several reasons. First, PBMC include the major
circulating targets of HIV infection, and knowledge of
overall expression is the logical first step towards charac-
terizing cell subtype expression. Second, if an elite sup-
pressor miRNA profile exists and associates with PBMC,
isolating cells to measure that profile could be done with
standard laboratory equipment and minimal resource
commitment. Third, a miRNA profile of infected, viremic
PBMC is available for comparison [25]. To maximize
confidence in our results and minimize the possibility of
platform-specific errors, we used two high-throughput
platforms that operate on different principles and also
validated the expression of 25 small RNAs using indivi-
dual quantitative polymerase chain reaction (qPCR)
assays [29].
In this study, we show that specific miRNAs distinguish
u n i n f e c t e da n de l i t es u p p r e s s o rP B M Cf r o mP B M Co f
viremic patients. While ES have miRNA profiles that lar-
gely cluster with uninfected controls, separation is
incomplete, and some ES–specifically, those with the
lowest CD4+ T-cell counts–group with viremic patients.
Multiple miRNAs are positively or negatively correlated
with peripheral blood CD4+ T-cell count, and miRNA
expression changes cannot be explained solely by
declines in the CD4+ population during infection. Our
analysis identifies several miRNAs that have not been
previously described in association with HIV infection,
including miR-31, which distinguishes controls and ES
from viremic individuals and regulates a protein with
important implications for T-cell differentiation.
Results
NanoString miRNA profiling distinguishes control and ES
from viremic individuals
RNA was isolated from peripheral blood mononuclear
cells (PBMC) of eight uninfected individuals, seven HIV-
1-infected elite suppressors (ES), and seven HIV-1-posi-
tive viremic patients (Table 1), using consistent purifica-
tion technique [30] and simultaneous isolation to avoid
batch effects. The NanoString hybridization platform
[31] was used to obtain miRNA expression profiles.
NanoString uses confocal microscopy to count fluores-
cently bar-coded probes, detecting and quantitating
nucleic acid molecules without amplification or introduc-
tion of position-dependent effects. Data were processed
using several normalization strategies, including quantile
normalization and normalization to a set of invariant
miRNAs; such normalization methods have been found
to yield consistent and reliable results [32,33].
Multiple analyses using two types of clustering revealed
that the NanoString PBMC miRNA profiles of viremic
patient discriminated them from PBMC of healthy
donors; however, the classification of elite suppressors
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ES samples tended to be more related to controls, but
several grouped with the viremic samples (Figure 1). This
finding was method-independent, as different clustering
methods and sets of features led to comparable results
(Figure 1A-D). In a second approach, class prediction, we
first assigned two classes: the viremic class and a class
with undetectable viral loads (control and ES). Seven
class prediction methods were used to predict the class
of all samples (Figure 2A). Sixteen samples (including all
controls, which are not shown) were consistently cor-
rectly classified. However, five samples were misclassified
by at least four of seven prediction methods (Figure 2A).
These samples were elite suppressors 4, 16, and 20 (ES
with the lowest CD4+ T-cell counts) and viremic samples
8 and 9, viremic patients with the lowest viral loads (see
Table 1). We repeated the analysis with a different group-
ing: classes of uninfected and infected (ES and viremic).
The prediction methods tended to misclassify elite
suppressors with high CD4+ T-cell counts as uninfected
(Figure 2B; controls again not shown because of consis-
tently correct classification), while viremic samples were
predicted correctly. Thus, by miRNA expression, ES sam-
ples with high CD4+ T-cell counts appear to relate most
closely to PBMC from healthy donors, and viremic sam-
ples with relatively low viral loads are more likely to
resemble ES or control samples. These results demon-
strate an intimate connection of miRNA expression with
CD4+ T-cell count and viral load, classical parameters of
HIV-1 disease progression.
Differential expression of individual miRNAs
We next queried the dataset to determine which indivi-
dual miRNA species were differentially regulated. We
observed that among miRNAs with significant expression
changes, levels were more often lower in viremic indivi-
duals. For example, control PBMC had higher mean
levels than viremic PBMC (Figure 3A) of miR-31 (3.9-
fold), miR-146b-5p (2.6-fold), miR-125b (2.5-fold), and
miR-29c (1.9-fold). Three miRNAs, miRs -9, -155, and
-181b/d, increased with infection (Figure 3B). For both
up- and downmodulated miRNAs, ES had mean expres-
sion that was either intermediate between control and
viremic samples or comparable to control levels.
TLDA profiling confirmed NanoString results and
identified additional targets
Many recent studies have examined the sensitivity and
specificity of different miRNA quantitation platforms
(including but not limited to [34,35]). Between-platform
concordance of results is less than perfect, with differences
arising from factors including, among others, feature sets
that do not overlap completely, including choice of incor-
porated endogenous controls; platform-specific sample
processing requirements; and relative sensitivity and speci-
ficity of individual probes and/or primers. Enhanced confi-
dence in results is therefore obtained by using multiple
platforms, as we have done in this study.
Because of these considerations and the relative novelty
of the NanoString technology, we used Applied Biosys-
tems TaqMan low-density arrays (TLDAs) as a second
profiling method. This approach employs reverse tran-
scription, pre-amplification, and a well-established system
of quantitative real-time polymerase chain reaction
(qPCR) to quantitate even low-abundance miRNAs with
high sensitivity. In addition, the TLDAs allowed us to
achieve broader coverage of the miRNome. Approximately
550 “features,” i.e., miRNAs, small RNAs, or genes, are
common to the Applied Biosystems and NanoString plat-
forms. NanoString measures over 100 non-overlapping
features, while the TLDAs expand the search space by
about 200 miRNAs. We used two TLDA cards each to
Table 1 ID numbers and characteristics of 22 PBMC
donors
ID Status CD4 VL NS TLDA qPCR
RT PA
7 Control + + +
11 Control + + + +
15 Control + + + +
22 Control + + + +
23 Control + + +
24 Control + + + +
26 Control + + +
27 Control + + + +
4 (ES4) ES 678 < 50 + + + +
5 (ES24) ES 1491 < 50 + + + +
10 (ES6) ES 1139 < 50 + + + +
12 (ES3) ES 1241 < 50 + + + +
16 (ES8) ES 593 < 50 + + + +
20 (ES25) ES 572 < 50 + + +
21 (ES18) ES 1762 < 50 + + + +
1 Viremic 383 55990 +
6 Viremic 326 44440 + + + +
8 Viremic 348 12480 + + +
9 Viremic 475 8190 + + + +
13 Viremic 490 155000 + + + +
14 Viremic 213 105660 + + + +
18 Viremic 413 19680 + + + +
Numerical designations are presented along with status (Control, Elite
Suppressor, or Viremic), CD4 counts (ES and Viremic), and Viral Load (VL,
copies/mL; < 50 = below the limit of clinical assays). Plus signs in the
rightmost columns indicate which platforms were used to assay miRNA in
each sample: NanoString (NS), TaqMan low-density array (TLDA), and
individual quantitative PCR assay (qPCR). The latter was performed with both
reverse-transcribed-only (RT) and reverse-transcribed/pre-amplified (PA)
material. For ES, two identification codes are given: first, the numbers used in
this study to blind samples, and second, the designation used in previous
studies using samples from these patients, including [44,55,56].
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all but one of which had been assayed by NanoString.
The TLDA results validated the NanoString findings
and also revealed additional candidates for differential
expression status (Figure 4). miRNAs with significant
downmodulation confirmed by both platforms included
miR-31, let-7g, and miR-146b-5p (Figure 4A); TLDA
results indicated 10-fold, 1.5- fold, and 2.7-fold downre-
gulation for these miRNAs, respectively. Several miRNAs
that ranked highly in the NanoString assessment of dif-
ferential expression were found by TLDA to have greater
fold change expression, a result that may be consistent
with a slight compression of data by NanoString for
some features as has been reported for hybridization
arrays [36]. The TaqMan arrays also identified additional
miRNAs as upregulated in viremics and/or ES (Figure
4B), including miRs -16 and -22, or downregulated, such
as miR-31* (the hairpin partner of miR-31) and miR-
1275. Differential expression of miR-29c (and all miR-29
family members together) was significant by NanoString;
in the TLDA results, miR-29a was underexpressed in
PBMC from viremics. Whereas let-7e was the most
highly expressed let-7 family member in the TLDA data-
set, by NanoString it was the least abundant. However,
Figure 1 Hierarchical clustering of NanoString miRNA profiling results. NanoString miRNA profiling results for PBMC RNA of eight control
(C, blue), seven elite suppressor (ES, red), and six viremic (V, green) donors were log-2 transformed and quantile normalized. Values at least one
standard deviation above background were included. Data were filtered using one-way analysis of variance (ANOVA, A, C, D) or t-tests with
Welch approximation (B). Features with significant difference at p < 0.05 (A, about 50 features) or p < 0.01 (about 20 features, B-D) were used for
hierarchical clustering of samples by Euclidean distance or Pearson correlation and average linkage, as indicated. Additional tests using complete
linkage were performed with comparable outcome (not shown).
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and let-7g–found by both methods to be differentially
regulated–had a similar position in both (Figure 5).
These results underscore the advantages of profiling with
multiple methods: miRNAs not assayed by one platform
(e.g. miR-181b by TLDA or miR-31* by NanoString) may
be covered by another, and nonlinear or low-sensitivity
assays, which will inevitably be found on any platform,
can also be complemented. Most importantly, concor-
dant data bolster confidence in results.
Validation by individual stem-loop quantitative PCR
To validate our results further, we chose a focused
group of more than 25 small RNAs for follow-up by
individual quantitative PCR assay. Individual assays dif-
fer from those performed in the TaqMan cards in
Figure 2 Incorrect class predictions of ES and viremic samples relate to CD4 count and viral load. Eight control, seven ES, and six viremic
samples were grouped as control+ES vs. viremic (A) and infected vs. uninfected (B). Seven class prediction methods were applied to these
groups: Compound covariate, diagonal linear discriminate analysis, 1-nearest neighbor, 3-nearest neighbors, nearest centroid, support vector
machines, and Bayesian compound covariate predictor. The number of incorrect class predictions for each ES and viremic sample is shown.
Controls are omitted due to a high level of correct predictions for uninfected samples. CD4 count gradients for ES and viral load gradients of
viremic samples are indicated with open and filled triangles, respectively (not to scale). ES (open bars) with the lowest CD4 counts were most
likely to be misclassified with viremic samples in the comparison of control and ES with viremic samples (A). The class of ES with the highest
CD4 counts was most likely to be incorrectly predicted when the two classes were infected and uninfected.
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replicates to be tested than is feasible with TaqMan
arrays. miRNAs were measured in reverse-transcribed
samples, reverse transcribed samples that were also pre-
amplified, or both (Figure 6). The ten small RNAs quan-
tified in both types of sample were miRs- 27a, -29a,
-29c, -31, -34a, -125b, -150, -155, and -221, along with
the snRNA U6. Few substantial differences between pre-
amplified and unamplified samples were found (for
representative comparisons, see Figure 7). The individual
miRNA assays confirmed many of the previous results,
including the relationship of the three classes by hier-
archical clustering and the tendency of ES with low
CD4+ T-cell count to cluster with viremic patients
(Figure 8). Again, both miR-31 and miR-31* were
expressed at significantly higher levels in control and ES
PBMC (whether grouped together or analyzed sepa-
rately) than in cells from viremic patients. Although the
elite suppressor miR-31 levels were closer to those of
control samples, they also covered a wider range. Levels
of miR-181b–elevated according to NanoString but not
tested by TaqMan array–were indeed higher in viremic
patients than in controls or ES.
Confidence-based hierarchy of differentially regulated
miRNAs
Integrating the results of the three profiling methods, we
constructed a list of presumptive differentially expressed
miRNAs based on confirmation by independent assays
and significance of expression differences of controls and
ES from viremic patients (Table 3). We included only
those miRNAs that had apparently high expression levels
as defined by cycle of amplification by quantitative PCR
(Ct < 30) or at least two standard deviations above back-
ground (NanoString). The highest levels of confidence, in
descending order, are associated with the following ten
Figure 3 NanoString profiling indicates differential regulation of specific miRNAs. Most differentially expressed miRNAs were
downregulated in viremic samples (A), although upregulated miRNAs were also observed (B). The final panel in (A) shows the geometric mean
of the three miR-29 family members for each sample. Quantile normalized values for miRNA species in each sample were plotted as fold change
in comparison with the mean expression of each respective miRNA within the uninfected control group. Significance was assessed by Kruskal-
Wallis test followed by Dunn’s multiple comparison test, using the absolute distance of normalized expression values from the control mean.
Asterisks represent p-values: * = p < 0.05; ** = p < 0.01, *** = p < 0.001.
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Figure 4 Individual miRNAs: TaqMan low-density array profiling results. Downregulated (A) and upregulated (B) miRNAs were identified
from quantile-normalized TaqMan low-density array data. Significance was assessed as described for Figure 3. Asterisks represent p values:
* = p < 0.05; ** = p < 0.01, *** = p < 0.001.
Figure 5 Relative let-7 family member abundance by NanoString and TLDA. Relative expression of the indicated let-7 family members
(averaged across all samples) was calculated by comparison with one, set equal to expression of the lowest-expressing family member
according to each platform: let-7e (NanoString) and let-7c (TLDA).
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cantly (p < 0.05) downregulated according to all three pro-
filing methods. miRs -31*, -181b, and -9 were assayed by
only two of the three methods, but were significant in
both. miR-29a changed significantly (TLDA, qPCR), or
trended in the same direction (NanoString) with p < 0.1.
For miR-16, miR-146b-5p, and let-7g, significant changes
were found by two methods, but not the third.
miRNA correlations with viral load
Having established that expression of miRNAs differs sig-
n i f i c a n t l ya c r o s st h et h r e es a m p l ec l a s s e s ,w ew i s h e dt o
discover what relation, if any, these miRNAs have to dis-
ease progression. Accordingly, we sought to identify corre-
lations of miRNA expression (individual qPCR assays)
with two important clinical parameters of HIV disease:
peripheral blood viral load and CD4+ T-cell count.
Figure 6 Individual qPCR miRNA results. Selected results of individual quantitative PCR assays, with fold change for each sample depicted as
compared with the mean of uninfected controls. Samples were normalized (delta-Ct) to the geometric mean of the most invariant twelve RNAs
of 23 measured RNA species. Shown are miRNAs downregulated (A) or upregulated (B) in viremic PBMC samples. Asterisks represent p values: *
= p < 0.05; ** = p < 0.01, *** = p < 0.001; statistical calculations were done using delta-delta Ct values, not the exponential fold change values.
Input materials for each assay were the products of reverse-transcription (RT) or of reverse-transcription and pre-amplification (PA). Where both
RT and PA were done, the average of delta-delta Ct values was taken. Three to six replicates were performed for each sample.
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has previously been presented for several miRNAs,
among them miRNAs identified here: miR-29 family
members [37], miR-125b and miR-150 [15]. Consistent
with a potential regulatory role, each of these miRNAs
was expressed at higher levels in PBMC from elite sup-
pressors than in cells from viremic individuals (although
it must be noted that even in ES, the levels of 125b and
150 were lower than in controls). In contrast, within the
viremic group, there were no negative correlations with
viral load. Two positive correlations attained (p < 0.05)
or approached (p < 0.1) significance: miR-342-3p and
the putative HIV modulator miR-125b (Figure 9).
CD4+ T-cell count and miRNA expression
In contrast, both negative and positive correlations with
CD4 cell counts were found when ES and viremic
patients were grouped together (Table 2). miRs-150,
-29a, -31, and -31* were significantly (p < 0.05) posi-
tively correlated with CD4 counts, while miR-181b was
negatively correlated. Three additional miRNAs had
negative correlations that approached significance (p <
0.1). When analysis was restricted to elite suppressors,
an additional positive correlation with miR-34a was
revealed (Table 2). Although correlation analyses with
small numbers of samples must be interpreted with
appropriate caution, the number and significance of
these correlations suggests biological relationships
between miRNA expression and HIV disease
progression.
CD4+ T-cell decline does not explain all differential
expression of miRNA
The most obvious explanation for the correlation of
CD4+ T-cell counts with miRNA expression is the well-
characterized population shift of blood cell subsets that
Figure 7 Comparison of results from qPCR assays with reverse-transcribed or pre-amplified input. Three representative examples of
assays performed with both reverse-transcribed RNA (RT) and reverse-transcribed, then pre-amplified samples. The average, calculated as
described in the Figure 7 legend, is also shown. Few substantial differences were observed between assays using samples derived with the two
pre-processing variations.
Witwer et al. Retrovirology 2012, 9:5
http://www.retrovirology.com/content/9/1/5
Page 9 of 15occurs during HIV infection. Thus, a hypothetical
decline of CD4+ T-cell-specific miRNAs would proceed
in proportion with CD4+ T-cell depletion, accompanied
by an increase in miRNAs specific to other cell types.
However, our data suggest that cell subset decline alone
does not explain all of the observed variation. In our
study, the highest observed CD4+ T-cell count was
eight times greater than the lowest count, but several
miRNAs varied more greatly, e.g., by 100 fold (miR-31*).
miRs -16 and -150 varied only slightly, but were none-
theless correlated with CD4+ T-cell count–and with
opposite signs. Additionally, based on the expression of
several miRNAs, even ES with high CD4+ T-cell count
closely resemble viremic individuals (Figures 3, 4, 6).
Discussion
We show for the first time that HIV-1-positive elite sup-
pressors are characterized by a PBMC miRNA profile
that in general resembles that of uninfected individuals.
However, we also find that ES, on the basis of miRNA
expression, are not an entirely homogenous group, and
that different mechanisms, shaped or marked by differ-
ent miRNA expression patterns, underlie elite control in
different individuals. We demonstrate further that
miRNA expression is closely tied to CD4+ T-cell count
in both ES and viremic patients, but that CD4 + T-cell
counts do not fully explain the observed differences in
miRNA profile. We describe significant differential
expression of several miRNAs in control, ES, and vire-
m i cp a t i e n t st h a th a v en o tp r eviously been reported in
connection with HIV-1 infection, e.g., miR-31 and its
star partner, miR-31*. Confidence in our findings is bol-
stered by rigorous cross-validation by two profiling plat-
forms, multiple-replicate testing by individual qPCR
assays, and the use of multiple data normalization and
analysis methods to ensure method-independence of
results.
Figure 8 Agglomerative hierarchical clustering of samples by
miRNA expression: individual qPCR assays. Results of 23
individual small RNA assays were normalized to the geometric
mean of the twelve most invariant RNAs and subjected to
unsupervised hierarchical clustering. Euclidean distance and
complete linkage was used.
Table 3 Ranking of findings by strength of evidence
across platforms
NanoString TLDA qPCR
miRNA p FC p FC p FC
miR-31 0.0059 -3.9 0.0026 -10.3 0.0040 -9.2
miR-125b 0.0419 -2.5 0.0066 -4.5 0.0090 -3.6
miR-150 0.0071 -1.9 0.0261 -1.6 0.0003 -1.6
miR-31* NA 0.0043 -10.1 0.0195 -8.5
miR-9 0.0033 1.8 0.0489 4.1 NA
miR-181b 0.0092 1.8 NA 0.0400 1.6
miR-29a < 0.1 0.0117 -1.5 0.0180 -1.7
let-7g 0.0004 -1.7 0.0028 -1.5 NS
miR-16 NS 0.0061 1.5 0.0001 1.5
miR-146b-5p 0.0025 -2.6 0.0020 -2.7 NS
miR-155 0.0071 1.5 NS 0.0690 1.3
miR-34a < 0.1 0.0514 3.6 0.0040 3.1
For NanoString, TaqMan low-density array (TLDA), and quantitative PCR
(qPCR), miRNAs are presented according to the estimated strength of
evidence for differential regulation between viremic patients and controls:
bold (p < 0.05 for each method with which the respective miRNA was
measured); italics (p < 0.05 for two of three); and regular font (p < 0.05 for
one platform and p < 0.1 for at least one other). Each of the listed miRNAs
had relatively high levels of expression across samples: more than two
standard deviations above background (NanoString) and/or amplifying before
a threshold cycle of 30 by TaqMan assay. Abbreviations: p = p value; FC =
mean fold difference from control (positive or negative as indicated); NS (not
significant) refers here to p > 0.1; NA: not measured with the indicated
method. miR-150 values for NanoString and TLDA are rendered in bold italics
to indicate quantile normalization limitations at expression extremes (miR-150
is one of the most abundant miRNAs in PBMC).
Table 2 Correlations of miRNA expression and CD4+ T-
cell count
Negative correlation Positive correlation
miRNA p-value miRNA p-value
miR-181b < 0.002 miR-31 < 0.001
miR-16 0.051 miR-31* < 0.004
miR-130b 0.051 miR-29a 0.015




For all infected samples and for all miRNAs measured with multiple replicates
by quantitative PCR, Pearson product-moment correlation coefficients were
calculated and corresponding p-values were determined using XLStat. An
alpha of 0.05 was considered significant; additional results that approached
significance are also shown. miR-34a (**) was significantly correlated only
when the elite suppressors were considered alone.
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sors as a group display a pattern of expression for several
specific miRNAs (e.g., miR-125b and miR-150) that clo-
sely resembles that of viremic patients. This finding gives
rise to several hypotheses. The similar levels of some
miRNAs in all infected samples may imply that immuno-
logic responses to the presence of even low levels of virus
and/or an immunologic imprint in the early phase of
infection are sufficient to effect reduced expression of
specific miRNAs. Alternatively, it is possible that elite
suppressors, even prior to infection, maintain lower base-
line levels of these miRNAs in comparison with the gen-
eral population, and that this is protective or indicative of
mechanisms of protection. These hypotheses should be
tested in longitudinal studies.
A second major implication of our results for miRs-
125b and -150 (as well as -382, although it does not
reach significance) has to do with the reported role of
these miRNAs in latency and control of viral replication
[15]. We find no negative correlation of these miRNAs
with viral load of viremic patients. In fact, there is a posi-
tive trend for miR-125b and viral load. Although ES may
have slightly higher levels of these miRNAs than viremic
patients, the difference does not seem to be of sufficient
magnitude to explain the profound gap in viral loads. It
is of course possible that elite suppressors experience a
significant decline of these miRNAs in the global PBMC
population, but that a small number of specific cells–per-
haps infected cells–experience an increase that keeps
viral replication in check.
Conversely, the observed alterations in PBMC miRNA
expression cannot be attributed solely to infected cells.
For miRNAs that are less abundant in PBMC from vire-
mic patients, downregulation must be due almost entirely
to bystander effects. Only a small percentage of PBMC
are infected in HIV-positive individuals. Thus, even if
specific PBMC miRNAs were absent from infected cells,
this difference would be undetectable in the overall
PBMC population. For overexpressed miRNAs, as well,
bystander effects would have to be invoked unless
infected cells upregulated these miRNAs by orders of
magnitude. Although possible, miRNA expression differ-
ences of hundreds- or thousands-fold are rarely observed
in vivo or in vitro. We conclude that most of the expres-
sion differences we observe are the result of host
responses to infection, indirect effects of viral products,
or both.
In addition to miRNAs with known roles in general
HIV-1 infection, we describe several previously unre-
ported associations of miRNAs with HIV-1 infection and
progression. For three reasons, we suggest that at least
one of these miRNAs, miR-31, has widespread implica-
tions for the interplay of HIV and T cell identity in
latency and disease progression. First, miR-31 expression
differences distinguish cells that influence HIV disease:
previous publications consistently report that T-regula-
tory cells contain lower levels of miR-31 than do other
T-cells [38,39]. Second, miR-31 is induced by CCAAT/
enhancer binding protein beta (C/EBP beta) [40], specific
isoforms of which can either inhibit or stimulate retro-
viral replication [41,42]. Third, the validated target of
miR-31, the special AT-rich binding protein 2 (SATB2)
[43], is part of a gene regulatory family needed for differ-
entiation within the T-cell lineage. These observations,
along with the consistent and profound downmodulation
of miR-31 in PBMC of viremic patients and, to a lesser
extent, in cells of some elite suppressors, demand experi-
m e n t a t i o no nh o wt h ep r e s e n c ea n da b s e n c eo ft h i s
miRNA affect T-cell differentiation and activation in the
context of HIV infection and latency.




















































Figure 9 Correlation of miR-125b and miR-342-3p with viral load. Correlations were calculated for all miRNAs analyzed by qPCR and for all
viremic individuals. The top two correlations by the Pearson method are shown, along with the coefficient of determination. The y-axis units are
negative delta-delta Ct (normalized, then related to the mean expression of control samples), which represents relative abundance. Viral load is
displayed on a log (2) scale.
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miR-150, and others in PBMC during infection are the
result of regulation and are not entirely (if at all) due to
CD4+ T-cell decline. This conclusion is strongly sup-
ported by a recent study of miRNA profiles in specific
blood cell populations [38]. With the possible exception of
miR-125b, miRNAs that are positively correlated with
CD4+ T-cell count in our work are not found exclusively
in CD4+ T-cells or naïve T-cells and thus could not be
expected to decline to the observed extent even with com-
plete CD4+ T-cell depletion. Indeed, some miRNAs that
have been found at high levels across PBMC subsets (miR-
16) or are even enriched in CD4+ T-cell subsets (miR-181
family members, miR-130b) [38]–and would therefore be
expected to decline along with CD4+ T-cells–are, to the
contrary, negatively correlated with CD4+ T-cell count.
Further work is needed to characterize the effects of HIV
and immune responses on miRNA expression in PBMC
and specific cell types both in vivo and, as far as possible,
in primary culture ex vivo.
Several pioneering studies have already initiated the pro-
cess of answering these questions, foremost among them
the work of Houzet, et al. [25] and Huang, et al. [15].
Building on earlier investigations of HIV and miRNA
using HIV-1-transfected or -infected cell lines [16,17],
Houzet, et al. reported differential regulation of miRNAs
in PBMC of HIV-infected, viremic individuals. The direc-
tion of this regulation was primarily downward, consistent
with our results. Perhaps most importantly, our groups
both observed downregulation of miR-150 and miR-29
family members, which have been characterized as miR-
NAs with HIV regulatory roles. Although Houzet, et al.,
observed a greater number of significant differences
between controls and infected individuals than we report
here, we do not see this difference as a discrepancy, due to
the sizes of the respective studies, different study design,
and use of different profiling platforms. Instead, the simila-
rities of our finding–especially regarding latency-asso-
ciated miRNAs–are telling and important, and should
prompt additional follow-up studies.
Regarding the Huang, et al. study, we find significant
and consistent downregulation of two of five miRNAs
(miRs -125b and -150) that these authors found to be
associated with control of HIV-1 transcripts in CD4+ T-
cells and downregulated in CD4+ T-cells of HIV-1
patients [24]. We also observed that another of these five
previously reported miRNAs, miR-382, was downregu-
lated approximately two-fold, but not significantly, in
PBMC of both ES and viremic patients (not shown).
Interestingly, although the five miRNAs from the Huang,
et al. CD4+ T-cell study were reported to be downregu-
lated during differentiation of monocytes to macrophages
in a follow-up study [20], another group observed down-
modulation of only one of these five, miR-223 [23]. In
the future, multiple validation techniques and analysis of
larger numbers of samples will help to address the
important issue of miRNAs involved in HIV control and
latency in specific target cell types.
Of potential clinical importance, this study suggests
that miRNA profiles may serve as biomarkers for the
identification of ES who could benefit from closer moni-
toring and/or antiretroviral treatment (ART). Among the
ES examined here, three had distinctly lower CD4+ T-
cell counts. ES with low CD4+ T-cell counts have been
described previously [44-46]; one elite suppressor with a
low CD4+ T-cell count developed Kaposi’sS a r c o m a
despite undetectable viral load (46). For some ES with
declining CD4+ T-cell counts, ART has been initiated, in
some cases with positive CD4 response [44,47]. On the
basis of the individual qPCR results presented here, two
of the three elite suppressors with low CD4+ T-cell
counts are unambiguously clustered with the viremic
patients. It will be important to expand our investigations
to discover additional correlates of miRNA expression
and to determine whether miRNA profiles predict clini-
cal decline, facilitating the decision of when treatment
should be initiated in ES with declining CD4+ T-cell
counts.
Conclusion
This study, the first report of miRNA profiles in ES versus
viremic patients and uninfected donors, underscores the
important role of miRNA in antiviral immunity. That
miRNA expression is closely tied to–but not entirely
explained by–CD4+ T-cell decline during HIV disease
shows that miRNAs are involved in processes reflected by
traditional markers of HIV disease progression. Several
differentially expressed miRNAs identified here, such as
miR-125b and miR-150, have also been described pre-
viously and appear to influence control of HIV replication.
Our results indicate that this role of miRNA in viral
latency and control should be investigated longitudinally
and in the context of different host responses to infection.
Our data reveal heretofore unreported small RNA corre-
lates of disease and nonprogression, including miR-31 and
miR-31*, that we trust will prompt both biomarker devel-




Eight control, seven elite suppressor, and seven viremic
donors contributed blood to this study. Controls were
healthy, HIV-1-negative donors. The elite suppressors
consistently maintain a viral load below the limit of
detection (50 copies/mL) and had a mean CD4+ T-cell
count of 1048 cells/ul at the time of donation. No ES was
hetero- or homozygous for the CCR5 Δ32 genotype.
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and had mean viral loads and CD4+ T-cell counts of
57,350 copies/mL and 380 cells/ul, respectively.
PBMC isolation
Peripheral blood mononuclear cells were isolated from
fresh blood by Ficoll gradient separation. 1 × 10
7 cells
were mixed with 600 ul mirVana RNA lysis buffer
(Ambion, Austin, Texas, USA) to achieve lysis and inac-
tivate endogenous RNAses. Lysates were frozen at -80°C
until RNA purification.
RNA isolation and quality control
RNA was isolated from all samples in parallel to avoid
batch effects and the potential influence of slight differ-
ences in RNA isolation [30]. Thawed samples were pro-
cessed for total RNA isolation using the miRVana
miRNA isolation kit (Ambion) and following the manu-
facturer’s protocol. RNA concentrations and purity were
assessed by NanoDrop spectrophotometer. Quality con-
trol was performed by measuring the expression of sev-
eral small RNAs, including snRNA U6 and miR-16, with
individual TaqMan miRNA assays (Applied Biosystems/
Life Technologies, Carlsbad, California, USA).
NanoString analysis
RNA was diluted to 33 ng/ul and eight control, seven ES,
and six viremic samples were submitted to the Johns Hop-
kins Medical Institutes Deep Sequencing and Microarray
Core Facility for further processing by the NanoString
nCounter system (NanoString, Seattle, Washington, USA).
The NanoString miRNA panel detects 664 endogenous
miRNAs (with 654 probes), 82 putative viral miRNAs
from nine viruses including HIV-1, five housekeeping
transcripts [(actin beta (NM_001101.2), beta-2 microglo-
bulin (NM_004048.2), GAPDH (NM_002046.3), RPL19
(NM_000981.3), and RPLP0 (NM_001002.3)], and six
positive and eight negative controls (proprietary spike-in
controls). Unlike traditional hybridization microarrays,
NanoString does not associate targets with spatial coordi-
nates; instead, the system generates copy numbers of tar-
get-specific molecular barcodes attached to detection
probes, theoretically eliminating position-dependent
effects. Raw data, which are proportional to copy number,
were log-transformed and normalized by the quantile
method after application of a manufacturer-supplied
correction factor for 13 miRNAs. Data were filtered to
exclude relatively invariant features (IQR = 0.5) and fea-
tures below the detection threshold (defined by a cutoff
corresponding to approximately one standard deviation
above background levels) in at least half of the samples.
Using R/Bioconductor and the filtered dataset, linear
models for microarray data analysis (limma, [48]) was
employed with a contrast matrix for the following compar-
isons: Control vs. ES, Control vs. Viremic, ES vs. Viremic,
Viremic vs. Control and ES, and Control vs. Infected (ES
and Viremic). P values were used to rank miRNAs of
interest, and correction for multiple comparisons was
done by the Bonferroni method. Raw data that were above
background (analysis not sho w n ) ,a sw e l la st h ec o r r e -
sponding quantile-normalized data, were also imported
into MultiExperiment Viewer [49,50]. One-way analysis of
variance was performed for the three classes, and samples
were hierarchically clustered by Euclidean distance and
average linkage. Class prediction methods were applied
with BRB-ArrayTools [51].
TaqMan low-density arrays
The microarray cards used in this study detect 384 fea-
tures on each of two cards, ‘A’ and ‘B’: a negative con-
trol, three endogenous small RNA controls (one of them
in quadruplicate), and 377 human miRNAs. Reverse
transcription and pre-amplification were performed with
the manufacturer’s reagents (Applied Biosystems). Real
time quantitative PCR was performed with an ABI 7900
real-time PCR machine (Johns Hopkins DNA Analysis
Facility), and data were collected with the manufac-
turer’s SDS software. RQ Manager software (Applied
Biosystems) was used to process the array data. Thresh-
olds, set at 0.2, were checked individually and corrected
as necessary. Data processing was done as described
previously [6].
Accessibility of array data
Raw data and sets of quantile-normalized, filtered data
from NanoString and TaqMan low-density arrays were
deposited with the Gene Expression Omnibus (GEO,
[52]) and are accessible as SuperSeries GSE33617.
Individual RT-qPCR assays
TaqMan miRNA assays (Applied Biosystems) were per-
formed according to the manufacturer’s protocol and as
previously described [6] with either reverse-transcribed or
reverse-transcribed and pre-amplified samples. The small
RNAs assayed were miRs -16, -21, -22, -27a, -29a, -29c,
-31, -31*, -34a, -125b, -126, -130b, -146a, -146b, -150,
-155, -181b, -199a, -221, -223, -342-3p, -1274A, let-7b and
let-7g, and small RNAs RNU48 and snRNA U6. Delta-
delta Ct (ΔΔCt) analysis was performed, with normaliza-
tion to the geometric mean of the twelve least variant
small RNAs across samples and comparison of each sam-
ple with the mean expression of the control samples.
Results were not dependent on this normalization method,
as established by investigations of alternative normaliza-
tion methods, including normalization to the spliceosomal
small nuclear RNA U6 (snRNA U6, data not shown).
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Data processing and analysis were conducted using tools
from Microsoft Excel, GraphPad Prism (Kruskal-Wallis
with Dunn’s multiple comparison), XLStat (correlation
analyses by Spearman and Pearson, Kruskal-Wallis with
Conover-Inman multiple comparison), BRB-ArrayTools
(binary tree predictions, class prediction) [51], the Mul-
tiExperiment Viewer (TIGR; one-way ANOVA, hier-
archical clustering by Pearson correlation and Euclidean
distance, self-organizing maps, self-organizing tree algo-
rithms, k-means clustering) [49], and R/BioConductor
packages including limma (with Bonferroni correction)
[48] and HTqPCR (comparisons with Benjamini-Hoch-
berg correction [53] for multiple comparisons) [54]. Fig-
ures and tables were prepared using Microsoft Excel
and Word, GraphPad Prism, MultiExperiment Viewer,
Adobe Photoshop and Illustrator, BRB-ArrayTools, and
HTqPCR.
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